Search

In order to study the geochemical characteristics and sedimentary environment of the Middle Jurassic coal seam in the southwestern margin of the North China Plate, taking the coal of Yima Formation in Yima Basin as the research object to study the geochemical characteristics and sedimentary environment of Middle Jurassic coal seams in the southwest margin of the North China plate, based on the data from X-ray fluorescence spectrometer and plasma mass spectrometer. The results show that: The content of major element of SiO2, P2O5 and K2O are significantly higher, while the content of Al2O3 is lower compared with Chinese coals. Enrichment of Cs and deficit of Sb, Nb, Ta, Zr and Hf in trace elements. The rare earth elements are slightly enriched as a whole, with negative Eu anomalies and positive Ce anomalies, indicating that the coal seam was not affected by magma, hydrothermal and seawater, and the provenance is mainly terrigenous clastic. It shows that the coal forming environment in reductive environment, and the whole coal forming period is in semi-arid climate environment by the analysis of Th/U, V/ (V+Ni), Ce anomaly, Sr/Cu and climate index.

Background and objective Whether gemcitabine plus platinum chemotherapy is superior to gemcitabine or platinum single-agent chemotherapy for patients with non-small cell lung cancer (NSCLC) is still in dispute, and the aim of this study is to evaluate the efficacy and safety of gemcitabine combining platinum chemotherapy for patients with NSCLC. Methods We searched relevant randomized controlled trials (RCTs) from VIP, CBM, CNKI, the Cochrane library, PUBMED and EMBASE. We traced the related references and experts in this field and communicated with other authors to obtain the information that has not been found. We made quality assessment of qualified RCTs assessed by the exclusion and inclusion criteria and used RevMan 5.0 provided by the Cochrane Collaboration to perform meta-analysis. Results Four RCTs were eligible and included 984 patients. Meta analysis results suggested that: compared with gecitabine single-agent chemotherapy, the combination had a statistically significant benefit in increasing the response rate (OR=3.29, 95%CI: 1.79-6.05, P=0.000 1) and 2-year survival rate (OR=3.22, 95%CI: 1.45-7.12, P=0.004) while increased the risk of the incidence of adverse reactions, especially the grade 3-4 thrombocytopenia (RR=8.16, 95%CI: 1.71-39.07, P=0.009); compared with cisplatin single-agent chemotherapy, the combination had a statistically significant benefit in increasing the response rate (OR=3.51, 95%CI: 2.20-5.60, P

Background and objective It was unclear whether advanced non-small cell lung cancer (NSCLC) patients could benefit from erlotinib therapy. This study was aimed to evaluate the efficacy and safety of NSCLC patients treated with erlotinib. Methods The relevant randomized controlled trials (RCT) were searched from VIP, CMB, CNKI, PubMed, EMBASE and The Cochrane Library. The related references and experts in this field were traced, and other authors were communicated with to obtain the information that has not been found. Quality assessment of qualified RCTs assessed by the exclusion and inclusion criteria and RevMan 5.0 provided by the Cochrane Collaboration was used to perform meta-analysis. Results Three RCTs involving 2 969 patients were included. Meta analysis results suggested that erlotinib was superior to placebo for one year survival rate (OR=1.18, 95%CI: 1.01-1.38), tumor response rate (OR=1.24, 95%CI: 1.03-1.49), median overall survival, median progression-free survival and tumor responses duration. At the same time, the incidence of grade 3-4 skin rash (OR=16.33, 95%CI: 7.01-38.02) and diarrhea (OR=5.02, 95%CI: 2.93-8.60) of the adverse reactions was increased. Conclusion Advanced non-small cell lung cancer patients could benefit from Erlotinib therapy, but the incidence of skin rash and diarrhea was significantly increased, and in the absence of damage to the blood system, serious liver and kidney damage, cardiac toxicity, etc, there were no difference with placebo.

Background and objective Whether gemcitabine plus platinum chemotherapy is superior to gemcitabine or platinum single-agent chemotherapy for patients with non-small cell lung cancer (NSCLC) is still in dispute, and the aim of this study is to evaluate the efficacy and safety of gemcitabine combining platinum chemotherapy for patients with NSCLC. Methods We searched relevant randomized controlled trials (RCTs) from VIP, CBM, CNKI, the Cochrane library, PUBMED and EMBASE. We traced the related references and experts in this field and communicated with other authors to obtain the information that has not been found. We made quality assessment of qualified RCTs assessed by the exclusion and inclusion criteria and used RevMan 5.0 provided by the Cochrane Collaboration to perform meta-analysis. Results Four RCTs were eligible and included 984 patients. Meta analysis results suggested that: compared with gecitabine single-agent chemotherapy, the combination had a statistically significant benefit in increasing the response rate (OR=3.29, 95%CI: 1.79-6.05, P=0.000 1) and 2-year survival rate (OR=3.22, 95%CI: 1.45-7.12, P=0.004) while increased the risk of the incidence of adverse reactions, especially the grade 3-4 thrombocytopenia (RR=8.16, 95%CI: 1.71-39.07, P=0.009); compared with cisplatin single-agent chemotherapy, the combination had a statistically significant benefit in increasing the response rate (OR=3.51, 95%CI: 2.20-5.60, P<0.01) and 1-year survival rate (OR=1.67, 95%CI: 1.16-2.41, P=0.006) while increased the risk of the incidence of adverse reactions, especially the grade 3-4 thrombocytopenia (OR=28.55, 95%CI: 14.06-57.04, P<0.01). Conclusion Compared with single-agent chemotherapy, the combining can significantly improve the efficiency and survival rate while increase the toxicity rare. The results still need to be proved by high quality RCTs. [ABSTRACT FROM AUTHOR]

Background and objective It was unclear whether advanced non-small cell lung cancer (NSCLC) patients could benefit from erlotinib therapy. This study was aimed to evaluate the efficacy and safety of NSCLC patients treated with erlotinib. Methods The relevant randomized controlled trials (RCT) were searched from VIP, CMB, CNKI, PubMed, EMBASE and The Cochrane Library. The related references and experts in this field were traced, and other authors were communicated with to obtain the information that has not been found. Quality assessment of qualified RCTs assessed by the exclusion and inclusion criteria and RevMan 5.0 provided by the Cochrane Collaboration was used to perform meta-analysis. Results Three RCTs involving 2 969 patients were included. Meta analysis results suggested that erlotinib was superior to placebo for one year survival rate (OR=1.18, 95%CI: 1.01-1.38), tumor response rate (OR=1.24, 95%CI: 1.03-1.49), median overall survival, median progression-free survival and tumor responses duration. At the same time, the incidence of grade 3-4 skin rash (OR=16.33, 95%CI: 7.01-38.02) and diarrhea (OR=5.02, 95%CI: 2.93-8.60) of the adverse reactions was increased. Conclusion Advanced non-small cell lung cancer patients could benefit from Erlotinib therapy, but the incidence of skin rash and diarrhea was significantly increased, and in the absence of damage to the blood system, serious liver and kidney damage, cardiac toxicity, etc, there were no difference with placebo. [ABSTRACT FROM AUTHOR]

Objective To investigate the role of extracellular signal regulated kinase 1/2 （ERK1/2） in colitis through the regulation of NADPH oxidase and mitochondrial fission. Methods Mice models of acute colitis were induced by 3% dextran sulfate sodium （DSS）. Thirty C57BL/6J mice were randomly divided into six groups by random number table method： control group， 3%DSS group，1% dimethyl sulfoxide （DMSO） group， ERK1/2 inhibitor（PD98059） group， 3%DSS+1%DMSO group and 3%DSS+PD98059 group， with five mice in each group. The changes of body weight， colonic length， disease activity index and colonic histopathological changes of mice in the control and 3%DSS groups were evaluated， and the expression levels of ERK1/2， p-ERK1/2， Nicotinamide adenine dinucleotide phosphate oxidase 1 （Nox1） and Nox2 in colonic mucosa of mice were detected. Mice in 1%DMSO and 3%DSS+1%DMSO groups were intraperitoneally injected with 1%DMSO. Mice in the PD98059 and 3%DSS+PD98059 groups were intraperitoneally injected with PD98059. The colonic histopathological changes were evaluated among four groups， and the expression levels of Nox1， Nox2， Dynamin related protein 1 （DRP1）， p-DRP1-S616 and p-DRP1-S637 mitochondrial fission related proteins were detected. Mitochondrial fission of colonic epithelial cells in the control and 3%DSS groups was observed by transmission electron microscopy. The co-localization of Nox2 and mitochondrial outer membrane translocator enzyme TOM complex （TOMM20） in colonic mucosa of mice in two groups was analyzed by double-immunofluorescence staining. The correlation between relative expression levels of DRP1 and Nox2 mRNA in mouse colonic mucosa was analyzed in two groups. Results Compared with the control group， mice in the 3%DSS group exhibited body weight loss， shortened colonic length， increased disease activity index and increased colonic histopathological score. The expression levels of p-ERK1/2， Nox1， Nox2 in colonic mucosa of mice were significantly up-regulated in the 3%DSS group （all P < 0.05）. In mice with colitis， mitochondrial fission in colonic epithelial cells was increased， and the colonic mucosa co-localization of DRP1 and Nox2 was elevated， and the relative mRNA expression levels of both target genes were positively correlated （r = 0.678， P < 0.05）. ERK1/2 inhibitor PD98059 improved colonic histopathological changes in mice with colitis， and down-regulated the expression levels of Nox1， Nox2， DRP1， p-DRP1-S616 in colonic mucosa. Conclusion Inhibition of ERK1/2 may ameliorate colitis by down-regulating NADPH oxidase expression and alleviating mitochondrial fission.

The soluble HLA antigens in human serum and saliva were determined with microlymphocytoxicity inhibition test (MLIT).As compared with the results of positive and negative salive determined, the difference was very significant(P